Expression profiling and genomic DNA sequence comparisons are increasingly being applied to the identification and analysis of the genes that are involved in lipid metabolism. Not only has genome-wide expression profiling aided in the identification of novel genes that are involved in important processes in lipid metabolism such as sterol efflux, but also the utilization of information from these studies has added to our understanding of the regulation of pathways that participate in the process. Coupled with these gene expression studies, cross-species comparison (a technique used to search for sequences that are conserved through evolution) has proven to be a powerful tool to identify important noncoding regulatory sequences and novel genes that are relevant to lipid biology. An example of the value of this approach was the recent chance discovery of a new apolipoprotein gene (that which encodes apolipoprotein AV) that has dramatic effects on triglyceride metabolism in mice and humans. 
Introduction
Recent years have seen an explosion in genomic resources, including a variety of new strategies to address how genes are regulated. Genome-wide expression pro®ling has been a popular approach to identify patterns of gene expression that may involve common regulatory mechanisms. The recent abundance of genomic sequence data has also led to a focus on multiorganism sequence comparisons to annotate the human genome, including the identi®cation of sequences that participate in gene regulation. Comparative sequence based approaches for annotating the human genome are based on the observation that sequences that are conserved between multiple species are probably important because of selective pressures to maintain these sequences. The present review examines recent developments in gene expression and comparative sequence analysis, and how they are advancing our knowledge of the genes and pathways that are relevant to lipid metabolism.
Microarray technology
There are currently two common platforms for microarray expression pro®ling. The ®rst uses high-density oligonucleotide synthesis on a glass surface, whereas the second prints polymerase chain reaction ampli®ed DNA, usually from cloned complementary DNA products [1, 2] . In addition, the printing of presynthesized oligonucleotides of 50±70 bases in length has also enjoyed increasing popularity. Both technologies rely on the hybridization of the arrays with a pool of labeled targets, which usually represent a complex mixture of messenger RNAs of a biologic sample or a combination of experimental and control samples. Ratios of signal intensity are used to determine the relative abundance of messenger RNA for the samples being tested as compared with a reference sample.
Data analysis and collection
Once signal intensity data are collected from the arrays they need to be analyzed in a meaningful way. Some of the common issues that confront analysis of data from microarray experiments include issues of signal intensity that could be affected by target or probe abundance, background noise, and the random chance of obtaining extreme ratios. The way in which these issues are dealt with varies widely in the literature, but a common approach is to perform arbitrary intensity and ratio cutoffs of multiple experiments in order to identify genes that are differentially expressed between two groups under study. In a recent study conducted to identify those genes that had altered expression in HDL metabolism [3 . ], transgenic and knockout mouse liver gene expression was ranked on the basis of the t-statistic value determined from the gene-modi®ed group and a control group. This approach avoids the necessity of assigning intensity and ratio cutoffs because of the inherent variability of low-intensity genes that tend to decrease t-statistic values. However, no matter what approach is used to identify differentially expressed genes, it is commonly recognized that alternative followup strategies need to be employed to generate con®dence in the ®ndings of the array studies. Several recent reviews [4±6] have addressed the issue of microarray data analysis.
Although performing independent replicated experiments is important in drawing conclusions from microarray experiments and in reducing the likelihood of identifying false-positive results, single experiments may still be a useful screening strategy, depending upon the expected outcomes. This is exempli®ed in work reported by Buechler et al. [7 . ], in which a single array experiment on monocyte messenger RNA from a patient with high lipoprotein(a) levels and a patient with low lipoprotein(a) was performed to identify genes that were differentially expressed. The information from a single array was then used to examine additional patients using alternative, less high-throughput techniques. Those investigators found that the messenger RNA levels for plasminogen activator inhibitor-2 were signi®cantly different between the high and low lipoprotein(a) patients after ®rst identifying this candidate from the microarray screen. In this case differentially expressed genes that appear to be associated with high lipoprotein(a) levels could be identi®ed without the use of a large number of microarrays.
Expression profiling facilitated discovery of new genes in lipid metabolism
One of the more common applications of microarray data is in the identi®cation of genes that are involved in a speci®cally de®ned biologic process. This annotation of uncharacterized genes is an important process in furthering our cataloging of the functions of the compendium of genes in the human genome. An increasing number of studies have shown that useful insights can be gained concerning the functions of novel genes, based on conditions in which their expression is altered.
An early example of the usefulness of using microarrays in the identi®cation of disease gene candidates was in the study of Tangier disease. Among the several nearsimultaneous reports that identi®ed mutation in the ATP-binding cassette transporter A1 (ABCA1; also . ] used microarrays to search for transcripts that were induced by a liver X receptor (LXR) agonist in mouse liver and intestine. Mice treated with an LXR agonist showed a marked decrease in cholesterol absorption, suggesting that genes involved in this process may be affected. A transcript ABCG5 that showed similarity to the Drosophila ATP-binding cassette half-transporters (brown, scarlet, and white) was induced 2.5-fold in the livers and intestines of treated mice. Because the white gene in humans (ABCG1) has been implicated in cholesterol ef¯ux from macrophages [16, 17] , it was suspected that ABCG5 was also possibly involved in sterol transport processes. Further evidence for the involvement of ABCG5 in sitosterolemia came from mapping its complementary DNA to chromosome 2p21, where the sitosterolemia gene had previously been mapped. Mutations within ABCG5 and the nearby ABCG8 gene were subsequently shown to be responsible for the increased absorption of plant sterols in sitosterolemic patients. This was soon followed by a second study [18] in which ABCG5 was implicated in sitosterolemia based purely on mapping data.
The use of gene expression patterns to identify the functions of novel genes that are involved in the metabolism of lipids was further highlighted in a study of 300 expression pro®les from yeast that were mutated or chemically treated [19 . . ]. In that approach, gene functions were inferred from pro®le comparisons of transcriptional responses. The identi®cation of Erg 28 as a member of the ergosterol synthesis pathway (the major membrane sterol of yeast) arose from the analysis because the transcription pattern of Erg 28 closely followed that of other genes involved in sterol synthesis. A human homolog was subsequently identi®ed [20] that was found to be expressed in the testis and in some cancer cell lines. By combining the expression patterns of characterized genes that cluster together in a similar transcriptional pro®le with an uncharacterized gene across many experiments, those investigators were able to associate this gene with a putative biologic pathway. ] have also been demonstrated to activate nuclear hormone receptors. In situations such as this, in which a transcriptional pathway may be affected by a diverse range of conditions, combining the data from all of the conditions can help to identify those target genes that are speci®c to the transcription factor pathway and not due to other effects of the treatment condition.
One group of well-studied receptors, the peroxisome proliferator-activated receptors (PPARs), regulate expression of enzymes that are involved in fatty acid oxidation, lipoprotein metabolism, adipocyte differentiation, and glucose metabolism. In PPAR-a knockout mice, disruption of the PPAR-a gene resulted in upregulation of genes associated with amino acid metabolism and synthesis of amino acid derived products [27 . ]. A novel conclusion from that analysis was that the suppressive effect of fatty acids on urea cycle enzymes may be directed through PPAR-a at ureagenesis and ammonia detoxi®cation. In this case the application of a genome-wide expression study lacking any a priori assumptions led to the identi®cation of new pathways that may be affected by a major transcriptional regulator of fatty acid metabolism.
The involvement of nuclear hormone receptors in atherogenesis and in¯ammation has also become increasing evident through the use of expression pro®ling of macrophage foam cells that are intermediary in the development of atherosclerotic lesions [28 . ]. Related to this, Kohro et al. [29 . ] found that the gene encoding LXR-a was among the most induced genes in an analysis of macrophage differentiation. That study not only highlighted a new tissue of expression for this important transcriptional regulator, but also associated its expression to a cell type that is implicated in atherosclerotic foam cell formation.
Sequence comparison
The increasing availability of sequences from multiple organisms has given biologists an opportunity to utilize sequence comparison along with expression pro®ling to study gene regulation. ].
An example of how effective the availability of orthologous sequences from multiple species, coupled with visualization tools for capturing the information content of cross-species comparisons, is in the identi®ca-tion of noncoding regulatory elements in the constitutive liver enhancer of apolipoprotein AI (Fig. 1) . The region of the enhancer, which was initially identi®ed from intensive biologic studies [32] , stands out in a crossspecies sequence comparison plot (VISTA) as an island of noncoding sequence conservation among nonconserved, noncoding sequences. Similarly, the exons of apolipoprotein AI also stand out as islands of conservation. Although conservation does not tell us what a sequence does, its presence provides a genomically informed means to prioritize otherwise anonymous sequences for further biologic characterization. The identi®cation of conserved noncoding sequences that play a crucial role in cytokine expression of human chomosome 5q31 [33 . ] is an example of where a conservation of sequence alone led to the identi®cation of a noncoding region that plays a vital role in the regulation of several genes of importance in the in¯ammatory response.
One of the opportunities as well as challenges in deciphering gene regulation is to identify biologically active transcription factor binding sites. The small number of bases recognized by such mediators of gene expression results in an enormous number of falsepositive sites in genomic sequence. Advances in VISTA now allow for the identi®cation of putative transcription factor binding sites based on cross-species conservation, which dramatically reduces the number of these sites that are falsely positive. The Regulatory Sequence Analyzer (http://www-gsd.lbl.gov/vista/RegSeq.html) is a computational tool designed for high-throughput discovery of cis-regulatory elements (Loots GG et al., unpublished data), and uses cross-species sequence analysis and clustering of transcription factor binding sites to enrich for evolutionarily conserved sequences. The Regulatory Sequence Analyzer maximizes the identi®cation of functional sites and minimizes the number of false-positive transcription factor binding sites, facilitating the discovery of putative transcriptional regulatory elements. The visualization tool for alignment (VISTA) combines a global alignment program with a graphical tool for analyzing alignments that allows identification of conserved coding and noncoding sequences between species. The horizontal axis represents the human genomic sequence and the vertical axis indicates the percentage of identical nucleotides in a preset interval between human and another species across the alignment. In this case the analysis uses a 100-nucleotide window, which slides at 40-nucleotide increments. The four exons of apolipoprotein AI are indicated across the top and appear blue on the plot. Noncoding sequence at greater than 75% identity is shown in red. ]. ABCA1 human±mouse sequence comparison has shown that the conserved promoter region of the ABCA1 gene contains important sequences for regulation of expression by LXR-a. Another site of high sequence conservation was found within intron 37, where a conserved noncoding sequence of 88% identity and 498 base-pairs was identi®ed. The conserved region was also found in other species including rat, dog, rabbit, cow, and pig with 79±88% homology; however, its function remains uncertain.
Discovery of apolipoprotein AV through comparative sequencing
Cross-species sequence comparisons used for the discovery of regulatory sequences also can be used as a gene-®nding aid. This approach recently led to the discovery of a new apolipoprotein gene in a previously well studied region of the human genome [35
A human/mouse/rabbit sequence comparison analysis was undertaken of 200 kilobase pairs of the apolipoprotein AI/CIII/AIV region to identify evolutionarily conserved sequences with potential function near this cluster. As observed with many other genes, the exons for apolipoproteins AI, CIII and AIV, as well as de®ned regulatory elements including the apolipoprotein AI liver-speci®c enhancer, were conserved between human and mouse (Fig. 2) , indicating that functional constraints were present in the sequence. However, another large block of sequence conservation was evident 30 kilobases downstream of the apolipoprotein AIV gene. This region demonstrated not just sequence conservation between human and mouse but also sequence similarity to apolipoprotein AIV at both the DNA level and the predicted protein level. The identi®cation of expressed sequence tags matching the mouse genomic sequence suggested the region was transcribed, and analysis of the human and mouse genomic sequence predicted a protein of 366 amino acids and 368 amino acids in these two organisms, respectively. Structural analysis of both the human and mouse proteins predicted the characteristic amphipathic helices found in lipid-binding apolipoproteins, and antibodies raised to synthetic peptides of apolipoprotein AV demonstrated the presence of the protein in the VLDL and HDL fractions of plasma of humans and mice, providing further evidence that this was a novel apolipoprotein.
In order to assess the function of the protein, transgenic and knockout mice were created, and profound but opposite effects on plasma triglyceride levels, but not plasma cholesterol levels, were observed. Increased levels of human apolipoprotein AV in transgenic mice lowered triglyceride levels to a third those of normal mice, and apolipoprotein AV de®-ciency in the knockout mice raised triglyceride levels fourfold. An analysis of human apolipoprotein AV polymorphisms and lipid parameters in two large human association studies with different populations and study designs demonstrated a consistent association between sets of single nucleotide polymorphisms (haplotypes) and triglyceride levels and VLDL mass. The apolipoprotein AV genomic interval therefore represents a new, independent determinant of triglyceride levels in the human population.
Access to genomic resources
Expression pro®ling and sequence comparison are two approaches that have been applied with success in the study of gene regulation and in gene discovery. Although these two approaches rely heavily on the availability of genomic resources, the structure of some aspects of biomedical research (following the human genome program example) has changed in that individual research laboratories are frequently not obligated to generate the genomic data sets for their own research. The broader research community can now access these genomic tools and reagents through a number of programs. One of the most relevant programs for lipid researchers is the Programs for Genomic Applications (Table 1) , which was established to link genes to biologic function and to provide a resource for investigators. All of the resources and reagents, including animal models, expression pro®les and sequence comparisons, generated by this program are being made available to researchers to advance functional genomic research.
Conclusion
Many of the successful studies that have utilized expression pro®ling have also incorporated parallel knowledge of other metabolic or genetic features. In this regard, even very well studied areas have bene®ted from the application of new technologies. This was most evident in the application of interspecies sequence comparison of the apolipoprotein AI/CIII/AIV gene cluster. Advances in how we handle expression data and sequence data will enable us not just to de®ne the individual elements of the genome but also to organize them into the complex interaction of elements that regulate gene expression. 
